Foamix Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, November 11

REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce third quarter ended September 30, 2015 financial results and host a conference call and webcast on Wednesday, November 11.

Conference Call & Webcast 
Wednesday, November 11th @ 8am Eastern Time
Toll Free:888-438-5535
International:719-325-2448
Conference ID:8764273
Webcast:http://public.viavid.com/player/index.php?id=116591
  
Replays, through November 25th
Toll-Free:877-870-5176
International:858-384-5517
Conference ID:8764273

About Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

CONTACT: Ilan Hadar, CFO
         Foamix Pharmaceuticals Ltd.
         +972-8-9316233
         ilan.hadar@foamixpharma.com
         
         U.S. Investor Relations
         Michael Rice
         LifeSci Advisors, LLC
         646-597-6979
         mrice@lifesciadvisors.com

Ads